KSK Sudo

K Sudo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


K Sudo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • K Konno

    Rational Drug Design Laboratories, 4-1-1, Misato, Matsukawa-Machi, Fukushima 960–12, Japan

    2 shared publications
  • T Yokota

    Rational Drug Design Laboratories, 4-1-1, Misato, Matsukawa-Machi, Fukushima 960–12, Japan

    2 shared publications
  • K Shimotohno

    Institute for Virus Research, Kyoto University, Sakyo-ku Shogoin, Kyoto 606, Japan

    1 shared publication
  • M Matsushima

    Rational Drug Design Laboratories, 4-1-1, Misato, Matsukawa-Machi, Fukushima 960-1 2, Japan

    1 shared publication
  • S Shigeta

    Department of Microbiology, Fukushima Medical College, 1 Hikarigaoka, Fukushima 960–12, Japan

    1 shared publication
  • S. Shigeta

    Department of Microbiology, School of Medicine, Fukushima Medical University, Japan

    1 shared publication

Latest Publications

  • Open Access

    Inhibitory Effects of Podophyllotoxin Derivatives on Herpes Simplex Virus Replication

    by K Sudo, K Konno, S Shigeta, T Yokota

    Podophyllotoxin and its derivatives were examined for inhibitory effects on the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), including acyclovir-resistant virus and clinical isolates. Deoxypodophyllotoxin (RD4–6266) proved to be a highly potent and selective inhibitor of all HSV strains in MRC-5 cells. EC50 values of RD4–6283 (in which the methylenedioxy ring A is modified) for HSV-1 and -2 were inferior to those of deoxypodophyllotoxin. However, podorhizol (RD4–6277) and 5′-methoxy-podorhizol (RD4–6276), in which ring C is absent, did notinhibit HSV replication. Moreover, RD4–6266 also inhibited the production of infectious virus particles of HSV-1 KOS strain and HSV-2 G strain. In contrast, none of the podophyllotoxin derivatives were found to have an antiviral effect against influenza A virus, respiratory syncytial virus or human cytomegalovirus in doses not toxic to the cells.


  • Open Access

    Novel Hepatitis C virus Protease Inhibitors: 2,4,6-Trihydroxy,3-Nitro-Benzamide Derivatives

    by K Sudo, Y Matsumoto, M Matsushima, K Konno, K Shimotohno, S Shigeta, T Yokota

    This study evaluated the inhibitory effects of 2,4,6-trihydroxy,3-nitro-benzamide (THNB) derivatives against hepatitis C virus (HCV). protease and other human serine proteases. The inhibitory efficacy was tested with a reversed-phase HPLC assay system using a NS3-NS4A fusion protein as the HCV protease and a synthetic peptide substrate that mimics the NS5A-5B junction. Twelve THNB derivatives showed more than 50% inhibition at 100 μg mL-1. The most potent derivative was RD3-4082, with 50% inhibition at a concentration of 2.3 μg mL-1; this concentration was lower than those of other protease inhibitors reported previously. The most selective derivative was RD2-4039, with 50% inhibition at a concentration of 32.8 μg mL-1, a lower concentration than those against other serine proteases (chymotrypsin, trypsin, plasmin and elastase). These results suggest that the RD2-4039 skeleton is an important structure for inhibitory activity against the HCV protease NS3-NS4A.